Recent Advances in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Urology & Nephrology".

Deadline for manuscript submissions: 20 January 2026 | Viewed by 974

Special Issue Editors


E-Mail Website
Guest Editor
Department of Urology, School of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, 56429 Thessaloniki, Greece
Interests: neuroUrology; LUTS; functional urology and urodynamics; urinary biomarkers

E-Mail Website
Guest Editor Assistant
Urology Department 424 Military Hospital, Ring Road Efkarpia, 56429 Thessaloniki, Greece
Interests: andrology; female and functional urology; reconstructive urology

Special Issue Information

Dear Colleagues,

It is our pleasure to invite you to contribute to the upcoming Special Issue of Medicina entitled “Recent Advances in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia”. This issue will focus on the latest clinical and research developments in the diagnosis, management, and treatment of LUTS and BPH—conditions that continue to have a profound impact on patient quality of life and healthcare systems worldwide.

In recent years, significant progress has been made in understanding the pathophysiology, progression, and optimal therapeutic approaches for LUTS and BPH. Innovations in medical technology, imaging, minimally invasive procedures, and pharmacological therapies are transforming the standard of care. Furthermore, the integration of artificial intelligence, molecular biomarkers, and personalized medicine is paving the way for more accurate diagnosis and targeted treatment strategies.

This Special Issue aims to showcase original research articles, comprehensive reviews, and clinical studies that highlight these cutting-edge developments. Topics of interest include, but are not limited to, the following:

  • Advances in diagnostic tools and imaging techniques for LUTS or BPH;
  • Novel pharmacologic and surgical treatments;
  • Role of biomarkers and genetics in disease stratification;
  • Impact of lifestyle and comorbidities on LUTS or BPH progression;
  • Minimally invasive and robotic interventions;
  • AI and digital health tools in urology practice.

We warmly welcome your contributions and encourage you to share this opportunity with colleagues who may be interested. If you plan to submit a manuscript, please send us a working title and a brief abstract to facilitate a preliminary suitability check.

The submission deadline is 20 January 2026.

We look forward to your valuable contributions to this Special Issue.

Prof. Dr. Apostolos Apostolidis
Guest Editor

Dr. Efstathios Papaefstathiou
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • LUTS
  • BPH
  • minimally invasive treatment
  • digital health tools
  • biomarkers
  • microbiome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

14 pages, 466 KB  
Systematic Review
Complication Profile and Safety Outcomes of Aquablation in the Management of BPH
by Panagiotis Triantafyllou, Polyvios Arseniou, Stamatios Katsimperis, Ioannis Kyriazis, Ioannis Manolitsis, Patrick Juliebø-Jones, Bhaskar Somani, Arman Tsaturyan, Theodoros Karagiotis, Titos Markopoulos, Lazaros Tzelves and Andreas Skolarikos
Medicina 2025, 61(12), 2076; https://doi.org/10.3390/medicina61122076 - 21 Nov 2025
Viewed by 774
Abstract
Background and Objectives: Aquablation, a robot-assisted, heat-free resection technique, has emerged as a promising minimally invasive surgical therapy (MIST) for benign prostatic hyperplasia (BPH). Its precision and potential for preservation of sexual function distinguish it from traditional surgical options. This systematic review [...] Read more.
Background and Objectives: Aquablation, a robot-assisted, heat-free resection technique, has emerged as a promising minimally invasive surgical therapy (MIST) for benign prostatic hyperplasia (BPH). Its precision and potential for preservation of sexual function distinguish it from traditional surgical options. This systematic review aimed to evaluate the safety profile of Aquablation, with emphasis on perioperative complications and functional outcomes. Materials and Methods: We systematically searched PubMed/MEDLINE, Scopus, and the Cochrane Library through June 2025 in accordance with PRISMA 2020 guidelines (PROSPERO CRD420251074479). Eligible studies included randomized and non-randomized trials of Aquablation in men with BPH, reporting adverse events by type, frequency, or severity. Risk of bias was assessed with ROB-2 and ROBINS-I tools. Results: Forty-seven studies were included, spanning randomized controlled and prospective observational designs. Most complications were minor (Clavien-Dindo grade 1–2). Bleeding was the most frequent perioperative event, with transfusion required in 1–8% of cases, more often in large prostates. Severe complications (grade ≥ 3) were uncommon and usually related to bleeding or urinary retention. Long-term sequelae such as strictures or bladder neck contracture were rare. Compared with transurethral resection of the prostate, Aquablation yielded lower rates of ejaculatory dysfunction (10% vs. 36%), with continence and erectile function largely preserved. Outcomes were comparable to holmium laser enucleation, but Aquablation demonstrated superior ejaculatory preservation. Conclusions: Aquablation demonstrates a favorable safety profile across prostate sizes, with its greatest advantage being preservation of sexual function. While bleeding remains the principal perioperative concern, life-threatening events are rare. Further independent, long-term comparative studies are warranted. Full article
Show Figures

Figure 1

Back to TopTop